Price
No data yet.
Social Signal Score
Analyst Ratings
23 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric Venker
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 315
- Beta
- 0.84
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 33.08
Financials
Revenue
$0.00-100.0%Net Income
$-97.25MEBITDA
$-97.16MFree Cash Flow
$-83.22MEPS (diluted)
$-0.47Shares Outstanding (diluted)
206.67M+1966.7%Operating Expenses
$104.16MCash & Debt
$722.27MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-505.61M | $-2.77 |
| 2025 | $0.00 | $-413.84M | $-2.73 |
| 2024 | $0.00 | $-259.34M | $-1.88 |
| 2023 | $0.00 | $-210.96M | $-1.71 |
| 2022 | $0.00 | $-156.73M | $-1.43 |
| 2021 | $0.00 | $-107.43M | $-1.22 |
| 2020 | $0.00 | $-66.39M | $-1.54 |
| 2019 | $0.00 | $-448.00 | $-0.00 |
| 2018 | $0.00 | $-136.74M | $-13.68 |
Valuation
IMVThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
155+144.74%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·13d ago·Positive
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript Immunovant, Inc. ( IMVT ) Q2 2027 Earnings Call November 9, 2026 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.
View source ↗ - Newsbenzinga.com·13d ago·Neutral
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study Immunovant (NASDAQ:IMVT) announced on Monday positive efficacy results from a clinical trial evaluating IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis (D2T RA).
View source ↗ - Newsmarketbeat.com·13d ago·Negative
What Immunovant (IMVT) Said on Its Q2 Earnings Call Roivant reported $31 million in net revenue from the initial launch of LISRAYA and highlighted new rheumatoid arthritis data for IMVT-1402 during its fiscal second-quarter earnings call. CEO Matt Gline cautioned that the LISRAYA results covered only about five weeks on the market and included a boost from pharmacy inventory.
View source ↗ - Newsglobenewswire.com·13d ago·Positive
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026 IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 (92.5% vs. 75.6% placebo, p=0.0139) in Period 2 (randomized withdrawal design following open-label lead-in) of the potentially registrational trial in patients with difficult-to-treat rheumatoid arthritis (D2T RA) In exploratory analyses, ACR50 and ACR70 response rates for patients who remained on IMVT-1402 600 mg in P…
View source ↗ - News (RSS)seekingalpha·33d ago·Positive
Immunovant: Batoclimab 2.0 Bull Case Flawed By Mixed Data, Competitive Threats
View source ↗ - Newsbusinesswire.com·42d ago·Negative
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newszacks.com·59d ago·Negative
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
View source ↗ - Newsglobenewswire.com·60d ago·Negative
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improve…
View source ↗ - Newsglobenewswire.com·60d ago·Negative
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in impr…
View source ↗ - News (RSS)investing·102d ago·Neutral
Immunovant stock hits 52-week high at 41.37 USD
View source ↗
Earnings
Fri, Feb 5(in 2 months)
Consensus estimate $-0.64 per share
Typical surprise +10.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.47 vs $-0.74beat
- Thu, Aug 6$-0.75 vs $-0.63miss
- Wed, May 20$-0.73 vs $-0.59miss
- Fri, Feb 6$-0.61 vs $-0.72beat
- Mon, Nov 10$-0.73 vs $-0.72miss
- Mon, Aug 11$-0.60 vs $-0.69beat
Estimates and results for IMVT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMVT officers and directors.
- Bought
- —
- Sold
- $14.6m
0 trades
46 trades
- Pande Atulsold
- Girao Tiagosold
- Stout Jay Ssold
- Stout Jay Ssold
- Stout Jay Ssold
- Van Tuyl Christophersold
- Gloria Melaniesold
- Venker Ericsold
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMVT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
